drugset
drugset / Trial / NCT03438344

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT03438344 ↗

Phase 2 Withdrawn City of Hope Medical Center
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This randomized phase II trial studies how well multi-antigen cytomegalovirus (CMV)-modified vaccinia Ankara vaccine works in reducing CMV related complications in patients with blood cancer who are undergoing donor stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.

Timeline

Start
2018-12
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Vaccine — Intramuscular

Indications

Hodgkins lymphoma acute myeloid leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma disease related to hematopoietic stem cell transplant leukemia, myeloid, accelerated-phase myelodysplastic syndrome myelofibrosis